A Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pardoprunox (Primary) ; Pramipexole
Indications Parkinson's disease
Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
Acronyms VERMEER
Sponsors Solvay Pharmaceuticals

Most Recent Events

29 Jun 2012 Company added in the association field as reported by EudraCT.
29 Jun 2012 Planned number of patients changed from 330 to 390 as reported by EudraCT.
17 Jun 2010 Results presented at the 14th International Congress of Parkinson's Disease and Movement Disorders.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight